Denise Rossato Silva, Margareth Dalcolmo, Simon Tiberi, Marcos Abdo Arbex, Marcela Munoz-Torrico, Raquel Duarte, Lia D’Ambrosio, Dina Visca, Adrian Rendon, Mina Gaga, Alimuddin Zumla, Giovanni Battista Migliori
Abstract
Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the "white plague", and promising results are being reported.
Pharmacology, Toxicology and Pharmaceutical Science
17
9%
Biochemistry, Genetics and Molecular Biology
14
8%
Immunology and Microbiology
13
7%
Chemistry
12
7%
Other
21
12%
Unknown
72
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2020.
All research outputs
#7,994,699
of 25,461,852 outputs
Outputs from Jornal de Pneumologia
#134
of 719 outputs
Outputs of similar age
#129,850
of 344,029 outputs
Outputs of similar age from Jornal de Pneumologia
#5
of 17 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 719 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,029 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
